MedPath
TGA Approval

GENVOYA elvitegravir (150mg), cobicistat (150mg), emtricitabine (200mg) and tenofovir alafenamide (as fumarate) (10mg) fixed dose combination tablets (233398)

233398

GENVOYA elvitegravir (150mg), cobicistat (150mg), emtricitabine (200mg) and tenofovir alafenamide (as fumarate) (10mg) fixed dose combination tablets

Gilead Sciences Pty Ltd

January 15, 2016

Medicine

Medicine

Active

Registered

Product Information

Consumer Medicine Information

https://medical-cdn.nocode.com/drug_tga/8b8af93a27178a0153acfd60d9633aac.pdf

Product Information

https://medical-cdn.nocode.com/drug_tga/bebf943d5fede5f90e86d78582d5f536.pdf

Active Ingredients

cobicistat

elvitegravir

emtricitabine

tenofovir alafenamide fumarate

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GENVOYA elvitegravir (150mg), cobicistat (150mg), emtricitabine (200mg) and tenofovir alafenamide (as fumarate) (10mg) fixed dose combination tablets (233398) - TGA 批准文号 | MedPath